KRKA, D. D. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 125 EUR | 0.00% |
|
+0.81% | +13.64% |
| Mar. 14 | Tranche Update on Krka, d. d.'s Equity Buyback Plan announced on July 20, 2023. | CI |
| Mar. 14 | Krka, d. d. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 1.87B 2B | Sales 2025 * | 1.96B 2.08B | Capitalization | 3.85B 4.11B |
|---|---|---|---|---|---|
| Net income 2024 * | 343M 365M | Net income 2025 * | 359M 382M | EV / Sales 2024 * | 1.78 x |
| Net cash position 2024 * | 515M 548M | Net cash position 2025 * | 543M 579M | EV / Sales 2025 * | 1.69 x |
| P/E ratio 2024 * |
11.6
x | P/E ratio 2025 * |
11.1
x | Employees | 10,284 |
| Yield 2024 * |
5.59% | Yield 2025 * |
5.86% | Free-Float | 72.38% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +0.81% | ||
| Current month | -2.72% | ||
| 1 month | -1.57% | ||
| 3 months | +9.65% | ||
| 6 months | +15.74% | ||
| Current year | +13.64% |
1 week
122.00
128.00
1 month
122.00131.00
Current year
110.00131.00
1 year
100.00131.00
3 years
80.00131.00
5 years
54.00131.00
10 years
48.01131.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jože Colaric
CEO | Chief Executive Officer | 68 | 81-12-31 |
Brane Kastelec
DFI | Director of Finance/CFO | - | 96-12-31 |
Breda Zagar
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mojca Videmšek
BRD | Director/Board Member | 57 | 18-12-31 |
Franc Šašek
BRD | Director/Board Member | 57 | 83-12-31 |
Mateja Vrecer
BRD | Director/Board Member | 57 | 89-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 125 | 0.00% | 4,185 |
| 24-04-17 | 125 | +0.81% | 1,802 |
| 24-04-16 | 124 | +0.40% | 4,907 |
| 24-04-15 | 123.5 | -0.40% | 4,513 |
| 24-04-12 | 124 | 0.00% | 3,991 |
End-of-day quote Ljubljana S.E., April 17, 2024
More quotes
Krka dd Novo Mesto is a Slovenia-based company engaged in the production of pharmaceutical preparations. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services consisting of Spa resorts in Smarjeske Toplice, Dolenjske Toplice, Strunjan, Novo Mesto and Otocec. Krka dd Novo Mesto is a controlling company of the Krka Group that includes two subsidiaries in Slovenia, Terme Krka doo and Farma GRS doo, and over 20 subsidiaries abroad in such countries as Croatia, Germany, Sweden, Poland, Spain, United States, Ireland, among others.
Sector
Pharmaceuticals
Calendar
2024-05-16
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
125
EUR
Average target price
133.6
EUR
Spread / Average Target
+6.91%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +13.64% | 4.11B | |
| +20.25% | 43.54B | |
| +16.96% | 21.74B | |
| +8.22% | 13.02B | |
| +4.73% | 13.53B | |
| +33.20% | 11.28B | |
| -11.05% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +7.71% | 5.09B |
- Stock Market
- Equities
- KRKG Stock
